CA
NZ
UK
AU
IND
US
● An oversubscribed $22.5 million private placement has bought CNS Pharmaceuticals time, but the Houston company is using the cash to walk away from berubicin and TPI-287 and hunt for new assets, a strategy still unproven to investors.
● Cocrystal Pharma's oral antiviral CDI-988 has earned FDA Fast Track status for norovirus and entered a Phase 1b human challenge study, even as the small-cap developer works through a thinning cash balance and a leadership transition.
● SINTX Technologies has disclosed more than $3.2 million in contract manufacturing purchase orders, its first FDA-cleared implant on the market, and fresh analyst coverage. A thin balance sheet, recurring dilutive financings and a long history of reverse splits temper the narrative.
● Soligenix's confirmatory Phase 3 trial of HyBryte for a rare skin lymphoma was halted for futility in April 2026, ending years of anticipation and pushing the microcap toward a strategic reset centered on its Behçet's disease candidate amid a disclosed going-concern warning.
● A new U.S. coronavirus-compound patent and a fresh Health Canada generic approval arrive alongside a reverse stock split and dilutive share offering, underscoring both promise and financial strain at the small-cap drugmaker.
● Moleculin Biotech disclosed unblinded interim data showing its anthracycline Annamycin outperformed chemotherapy alone in relapsed AML, but a subsequent dilutive stock offering has erased much of the goodwill, sending shares down sharply into late July.
● NeuroOne Medical Technologies is scaling sales of its thin-film sEEG electrodes and OneRF ablation system, but a revenue-recognition restatement, a reverse stock split and a new at-the-market offering have complicated the story for investors in 2026.
● Nexalin's June 2026 Brazil pilot study showed a 77.8% anxiety response rate for its drug-free neurostimulation device, but the clinical progress is now overshadowed by a July 24 Nasdaq staff determination threatening to suspend NXL trading on August 4, 2026.
● Palatin Technologies has shifted its listing from NYSE American to the Nasdaq Capital Market and is advancing melanocortin receptor (MC4R) obesity candidates alongside its approved drug bremelanotide, while operating with a small cash balance and reliance on partner payments.
● Pasithea Therapeutics is pushing its oral MEK inhibitor PAS-004 through overlapping trials in rare-tumour and cancer settings, backed by three FDA designations and a $60 million cash cushion, ahead of an October poster at ESMO and NF1 data due in the fourth quarter.
Please wait processing your request...